First Time Loading...
C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.795 AUD -2.18% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. [ Read More ]

The intrinsic value of one CYC stock under the Base Case scenario is 3.857 AUD. Compared to the current market price of 1.795 AUD, Cyclopharm Ltd is Undervalued by 53%.

Key Points:
CYC Intrinsic Value
Base Case
3.857 AUD
Undervaluation 53%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Cyclopharm Ltd

Backtest CYC Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CYC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Cyclopharm Ltd

Current Assets 30.2m
Cash & Short-Term Investments 11.7m
Receivables 7.9m
Other Current Assets 10.6m
Non-Current Assets 15.7m
PP&E 9.2m
Intangibles 5.7m
Other Non-Current Assets 796.1k
Current Liabilities 8.7m
Accounts Payable 6.9m
Other Current Liabilities 1.7m
Non-Current Liabilities 5m
Long-Term Debt 4m
Other Non-Current Liabilities 973k
Efficiency

Earnings Waterfall
Cyclopharm Ltd

Revenue
27.8m AUD
Cost of Revenue
-10.3m AUD
Gross Profit
17.5m AUD
Operating Expenses
-26.1m AUD
Operating Income
-8.6m AUD
Other Expenses
3.9m AUD
Net Income
-4.7m AUD

Free Cash Flow Analysis
Cyclopharm Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CYC Profitability Score
Profitability Due Diligence

Cyclopharm Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 3-Years Revenue Growth
ROE is Increasing
31/100
Profitability
Score

Cyclopharm Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

CYC Solvency Score
Solvency Due Diligence

Cyclopharm Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Short-Term Solvency
94/100
Solvency
Score

Cyclopharm Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYC Price Targets Summary
Cyclopharm Ltd

Wall Street analysts forecast CYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYC is 3.876 AUD with a low forecast of 3.838 AUD and a high forecast of 3.99 AUD.

Lowest
Price Target
3.838 AUD
114% Upside
Average
Price Target
3.876 AUD
116% Upside
Highest
Price Target
3.99 AUD
122% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

CYC Price
Cyclopharm Ltd

1M 1M
-1%
6M 6M
-37%
1Y 1Y
+20%
3Y 3Y
-28%
5Y 5Y
+69%
10Y 10Y
+832%
Annual Price Range
1.795
52w Low
1.495
52w High
2.9
Price Metrics
Average Annual Return 15.9%
Standard Deviation of Annual Returns 69.48%
Max Drawdown -71%
Shares Statistics
Market Capitalization 168.9m AUD
Shares Outstanding 94 096 300
Percentage of Shares Shorted
N/A

CYC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cyclopharm Ltd

Country

Australia

Industry

Health Care

Market Cap

168.9m AUD

Dividend Yield

0.56%

Description

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

Contact

NEW SOUTH WALES
Unit 4 / 1 The Crescent, Kingsgrove
+61295410411.0
http://www.cyclopharm.com.au/

IPO

2007-01-18

Employees

48

Officers

CEO, MD, Company Secretary & Director
Mr. James S. McBrayer F.A.C.I.D., BSPharm, GDM, FAICD, AIM
Chief Operating Officer
Mr. Mathew Farag
Finance Manager
Mr. Graham N. Phillips
Global Head of Regulatory Compliance & Clinical Research
Dr. Mark Doverty
Head of Sales
Ms. Sally-Ann Cornelius
Head of Quality and Regulatory
Ms. Niamh McAree
Show More
Head of Service
Mr. Chris Quinn
Financial Controller
Ms. Sui Ling Cheah
General Manager of Canada
Mr. Lynn McLauchlin
Quality & Regulatory Manager
Mr. Gary T. Somerville
Show Less

See Also

Discover More
What is the Intrinsic Value of one CYC stock?

The intrinsic value of one CYC stock under the Base Case scenario is 3.857 AUD.

Is CYC stock undervalued or overvalued?

Compared to the current market price of 1.795 AUD, Cyclopharm Ltd is Undervalued by 53%.